Metabolic-associated fatty liver disease and sarcopenia: A double whammy

Figure 1 The pathways contributing to the progression of both liver and muscle dysfunction in metabolic-associated fatty liver disease and sarcopenia. MAFLD: Metabolic-associated fatty liver disease; FFAs: Free fatty acids; IL: Interleukin; TNF-α: Tumor necrosis factor alpha; NASH: Non-alcoholic steatohepatitis; FGF21: Fibroblast growth factor 21; GH: Growth hormone; IGF-1: Insulin-like growth factor 1.

Figure 2 Clinical complications associated with metabolic-associated fatty liver disease and sarcopenia. MAFLD: Metabolic-associated fatty liver disease.